RNA (Atrium Therapeutics) Current Accrued Expense: $6.98 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $11.46
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Current Accrued Expense?

Atrium Therapeutics RNA +2.50% 12 Current Accrued Expense is $6.98 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $6.98 Mil.

Atrium Therapeutics's quarterly Current Accrued Expense increased from Sep. 2025 ($5.61 Mil) to Dec. 2025 ($8.95 Mil) but then declined from Dec. 2025 ($8.95 Mil) to Mar. 2026 ($6.98 Mil).

Atrium Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($0.66 Mil) to Dec. 2024 ($1.19 Mil) and increased from Dec. 2024 ($1.19 Mil) to Dec. 2025 ($8.95 Mil).

Atrium Therapeutics Current Accrued Expense Related Terms

Atrium Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Current Accrued Expense Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Current Accrued Expense
0.66 1.19 8.95

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial 1.19 0.00 5.61 8.95 6.98
RNA
12GF Score
Atrium Therapeutics Inc RNA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $6.98 Mil mean?
Atrium Therapeutics (RNA) has a Current Accrued Expense of $6.98 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Current Accrued Expense too high?
Atrium Therapeutics' current Current Accrued Expense is $6.98 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Current Accrued Expense compare to KROS and PLX?
Atrium Therapeutics' Current Accrued Expense of $6.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Current Accrued Expense is $6.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Current Accrued Expense of $6.98 Mil. The current Current Accrued Expense is $6.98 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Current Accrued Expense is $6.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.46
Price